<DOC>
	<DOCNO>NCT02880046</DOCNO>
	<brief_summary>Purposes study : - Characterization polyfunctionality anti-tumor T lymphocytes use vitro inhibition PD-1/PDL-1 pathway - Study comparison polyfunctionality anti-tumor T lymphocytes cohort patient melanoma , lung cancer renal carcinoma . This cancer choose use anti-PD-1 anti-PDL-1 antibody - Comparison technique IFN-γ Elispot assay detection quantification anti-tumor T lymphocytes vitro blockade PD-1/PDL-1 pathway .</brief_summary>
	<brief_title>Study Polyfunctionality Anti-tumor T Lymphocytes Cancerology : Potential Biomarker Emerging Immunotherapies</brief_title>
	<detailed_description>In study immunomonitoring specific response T lymphocytes tumor-associated antigen base detection intracellular cytokine flow cytometry , stimulation all-tumor antigen blockade PD-1/PDL-1 interaction use . Peripheral blood mononuclear cell patient cancer stimulate 4 telomerase-peptides peptide overlap entire sequence survivin . This project study frequency role polyfunctionality anti-tumor T lymphocytes cancerology vitro technique detect polyfunctional T lymphocytes good sensitivity base removal inhibitory PD-1/PDL-1 pathway . It flow cytometry protocol various theoretical advantage term reproducibility dynamic monitoring functionality different sub-populations polyfunctional anti-tumor T lymphocyte . Moreover , allow study molecular mechanism involve proliferation polyfunctional anti-tumor T lymphocytes possibility sort sub-populations . The use all-tumor antigen allow use technique evaluate presence prognostic predictive value biomarker various cancer . Detection polyfunctional anti-tumor T lymphocytes biomarker anti-tumor lymphocytic adaptive immunity potential eligibility efficacy criterion new immunotherapy , anti-PD-1 anti-PDL-1 treatment .</detailed_description>
	<criteria>Patients affect melanoma ( LyteloMel ) , lung cancer ( TeloCap ) renal carcinoma ( EMIR ) cohorts medical oncology department CHRU Besançon ( France )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>immune response</keyword>
	<keyword>T lymphocyte</keyword>
	<keyword>PD-1/PDL-1 pathway</keyword>
</DOC>